Joincare(SH:600380)2023-11-28 04:13Product Development and Clinical Trials - The company is expecting significant market potential for the tobramycin inhalation solution if it successfully enters the medical insurance directory this year, with a projected scale of sales next year based on disease prevalence and patient numbers [1] - The company has submitted for production approval of the indacaterol inhalation powder in the second half of 2022, which could mark a major breakthrough in the inhalation powder field due to limited competition [1] - The company has initiated Phase III clinical trials for the innovative flu drug TG-1000, with over 70 clinical centers nationwide aiming to recruit 750 participants [3] - The innovative drug TG-1000 is designed to effectively inhibit both influenza A and B viruses, with advantages such as rapid action and good tolerance [3] Business Development and Strategic Focus - The company has focused on introducing innovative drugs through business development (BD) efforts, successfully signing two Phase I clinical drugs and one preclinical drug in the respiratory field this year [3] - Future BD efforts will target respiratory diseases, digestive issues, mental health, and assisted reproduction, emphasizing new targets and mechanisms, new administration methods, and expanding indications [3] - The company aims to establish a diverse product matrix in the respiratory field, combining innovative drugs with complex formulations [3] Sales and Marketing Strategies - The company has completed the establishment of a specialized sales team for respiratory products, covering a wide range of regions with approximately 300-400 sales personnel [4] - The digital marketing platform "Respiratory Expert Talks" has conducted over 100 live broadcasts, reaching over 5 million viewers and engaging more than 3 million users [4] - The health product segment achieved revenue of 132 million yuan from January to September 2023, representing a year-on-year growth of 60.12% [4] Shareholder Returns and Financial Performance - The company has completed multiple share buybacks, with total funds exceeding 2 billion yuan, and has consistently returned over 70% of net profit to shareholders through buybacks and cash dividends [4] - In 2023, the company completed a buyback plan of 3-6 billion yuan, repurchasing approximately 49.7 million shares for a total payment of 599.9 million yuan [4]